Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | AR | P10275 | 3/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.65 |
| ▸ | PGR | P06401 | 2/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | SNCA | P37840 | 2/20 | 0.65 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.65 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.65 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25867504 | 1.00 | SHBG (1.00) | SHBGCYP3A4CYP19A1LMNAHSD17B10 | |
| SCHEMBL2733158 | 1.00 | SHBG (1.00) | SHBGCYP3A4CYP19A1LMNAHSD17B10 | |
| SCHEMBL4916351 | 1.00 | SHBG (1.00) | SHBGCYP3A4CYP19A1LMNAHSD17B10 | |
| SCHEMBL10273612 | 1.00 | SHBG (1.00) | SHBGCYP3A4CYP19A1LMNAHSD17B10 | |
| SCHEMBL6695330 | 1.00 | SHBG (1.00) | SHBGCYP3A4CYP19A1LMNAHSD17B10 | |
| SCHEMBL24103268 | 1.00 | SHBG (1.00) | SHBGCYP3A4CYP19A1LMNAHSD17B10 | |
| SCHEMBL8986762 | 1.00 | SHBG (1.00) | SHBGCYP3A4CYP19A1LMNAHSD17B10 | |
| SCHEMBL24102492 | 1.00 | SHBG (1.00) | SHBGCYP3A4CYP19A1LMNAHSD17B10 | |
| SCHEMBL7139746 | 1.00 | SHBG (1.00) | SHBGCYP3A4CYP19A1LMNAHSD17B10 | |
| SCHEMBL13298151 | 0.89 | SHBG (0.80) | SHBGCYP3A4CYP19A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-20 | — | — | US | disclosed |
| WO-2021252761-A2 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | SHBG, CYP19A1, GNRHR | SHBG 1/4885CYP3A4 2085/4885CYP19A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.